Your session is about to expire
← Back to Search
Behavioural Intervention
CirrhosisRx CDS for Liver Cirrhosis
N/A
Recruiting
Led By Jin Ge, MD, MBA
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completetion, approximately 36 months
Awards & highlights
No Placebo-Only Group
Summary
This trial compares a new medical system to usual care for hospitalized patients with cirrhosis to see which one works better.
Who is the study for?
This trial is for adults over 18 years old who have been previously diagnosed with cirrhosis, as confirmed by specific diagnosis codes. It's not open to children, those without a proper cirrhosis diagnosis, or patients who aren't hospitalized.
What is being tested?
The study tests CirrhosisRx CDS against usual care to see if it better follows national quality measures and improves outcomes for hospitalized patients with cirrhosis.
What are the potential side effects?
Since this trial involves a decision support system rather than medication, traditional side effects are not applicable. However, there may be risks related to the management of patient care based on the system's recommendations.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completetion, approximately 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completetion, approximately 36 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Aggregate adherence to quality measures
Secondary study objectives
Inpatient mortality
Other study objectives
Adoption of CirrhosisRx
Average time spent on CirrhosisRx
Implementation of CirrhosisRx
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: CirrhosisRxExperimental Treatment1 Intervention
Providers in this arm will have access to the CirrhosisRx CDS system, which aggregates and organizes clinical data, presents them in clinically relevant/intuitive fashion for cirrhosis care, and linked to order sets consistent with national guidelines.
Group II: Usual CareActive Control1 Intervention
Providers in this arm will not have access to the CirrhosisRx CDS system.
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,885,844 Total Patients Enrolled
Jin Ge, MD, MBAPrincipal InvestigatorUniversity of California, San Francisco
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My liver is not severely damaged.I am under 18 years old.I can walk on my own without help.I am an adult with a history of cirrhosis diagnosed by specific health codes.
Research Study Groups:
This trial has the following groups:- Group 1: CirrhosisRx
- Group 2: Usual Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.